I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-

BOOS I O DUA

Dated: July 30 200 Signature:

Robin Torres

Docket No.: 587.PFUS

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of:

Haolun Jin et al.

Application No.: 10/585,504

0/585,504 Confirmation No.: 7676

Filed: February 14, 2008 Art Unit: 4161

For: PYRIMIDYL PHOSPHONATE ANTIVIRAL

COMPOUNDS AND METHODS OF USE

Examiner: McDowell, Brian E.

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Application No.: 10/585,504 Docket No.: 587.PFUS

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 07-1250, under Order No. 587.PFUS. A duplicate copy of this paper is enclosed.

Dated: July 30, 2008

Respectfully submitted,

Barry F. McGurl

Registration No.: 43,340 GILEAD SCIENCES, INC.

333 Lakeside Drive

Foster City, California 94404

(Fax) 650-522-5575 Attorney For Applicant